obesity paradox?—improved survival outcomes in mCRPC patients with a high body mass index (BMI)

[JRPnSD]

Vinayak G. Wagaskar, MBBS, highlights a study presented at the 2021 European Association of Urology Congress which reported evidence of the obesity paradox in patients with metastatic castration-resistant prostate cancer (mCRPC).

urologytimes.com/view/dr-wa...

[pjoshea13]

"The study enrolled 1577 patients with mCRPC enrolled across 3 phase 3 randomized control trials: ASCENT2, MAINSAL and VENICE. The median patient age was 69 years (IQR, 63-74) and the median BMI was 28 mg/m2 (IQR, 25-31)."

"Obese patients in this older age group tend to be taking medication for other conditions and we do not fully understand how these medicines interconnect,”"

e.g. it might have been wise to control for Metformin use.

-Patrick